September 2, 2020

Lynda Tussey, PhD joins Vaxess Technologies as Chief Development Officer


Vaxess adds veteran vaccine developer to team to lead clinical activities

Vaxess Technologies, a preclinical biotechnology company developing a pipeline of vaccines and therapeutics on the MIMIX smart release patch, has recently appointed Dr. Lynda Tussey to the position of Chief Development Officer. Dr. Tussey is a veteran vaccine developer with over twenty years of experience in the field. She brings a wealth of knowledge and expertise in clinical translation that will help advance Vaxess into Phase I clinical trials in 2021.

[Read the full article here]